Mira Pharmaceuticals (MIRA) Other financing activities (2022 - 2025)

Mira Pharmaceuticals (MIRA) posted Other financing activities of $158421.0 for Q4 2025, up 40.73% sequentially from $112569.0 in Q3 2025.

Mira Pharmaceuticals (MIRA) Other financing activities (2022 - 2025) Analysis & Trends

Mira Pharmaceuticals (MIRA) has 3 years of Other financing activities data on file, last reported at $158421.0 in Q4 2025.

Quarterly Other financing activities changed N/A year-over-year to $158421.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $270990.0 (up 242.86% YoY) and the FY2025 annual result came in at $292470.0, up 767.53% from the prior year.
Other financing activities climbed to $158421.0 in Q4 2025 per MIRA's latest filing, from $112569.0 in the prior quarter.
The five-year high for Other financing activities was $163684.0 in Q2 2023, with the low at -$353372.0 in Q3 2023.
Average Other financing activities over 3 years is $22068.7, with a median of $79415.0 recorded in 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Eli Lilly	1,066.16 Bn	1,060.88 Bn	16.22 Bn
2	Johnson & Johnson	611.69 Bn	589.64 Bn	15.96 Bn
3	AbbVie	444.34 Bn	434.99 Bn	10.78 Bn
4	Astrazeneca	284.94 Bn	277.05 Bn	12.61 Bn
5	Merck	224.23 Bn	218.58 Bn	12.09 Bn
6	Amgen	195.12 Bn	183.08 Bn	5.87 Bn
7	Gilead Sciences	156.45 Bn	148.73 Bn	5.52 Bn
8	Pfizer	136.01 Bn	123.24 Bn	-1.21 Bn
9	Novartis Ag	113.45 Bn	113.67 Bn	-
10	Mira Pharmaceuticals	22.51 Mn	11.48 Mn	-

Download Data